Hospital del Mar

Hospital del Mar Barcelona

Hospital del Mar. Barcelona

Donate to brain disease research

News

  • December 17th, 2024

    Positive results of the clinical trial of a drug to improve cognitive function in Down syndrome

    Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interactions and daily living for people with Down syndrome. These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal.

    Read more sobre "Positive results of the clinical trial of a drug to improve cognitive function in Down syndrome"

  • December 11th, 2024

    Having a good breakfast reduces cardiovascular risk

    Consuming 20-30% of daily energy intake in the morning influences key cardiovascular risk factors. People who consume the right amount of energy in the morning have 2-3.5% lower body mass index, less abdominal obesity (2-4% smaller waist circumference), 9-18% lower triglycerides, and 4-8.5% higher HDL cholesterol (the good cholesterol). Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol. The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.

    Read more sobre "Having a good breakfast reduces cardiovascular risk"

  • November 18th, 2024

    Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

    The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment.  This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors. This study is mainly supported by the Asociación Española Contra el Cáncer (AECC) through AUSONIA and has also received funding from the Breast Cancer Research Foundation (BCRF), Fundación BBVA through the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), which is one of VHIO's Institutional Programs focused on developing new advanced therapies.

    Read more sobre "Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors"

Events

Social commitment

  • Social commitment
  • Top 20
  • HPH Catalunya - Xarxa d'Hospitals i Centres Promotors de la Salut
Collaborating entity

© 2006 - 2025 Hospital del Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility